& MicroVision Investor Presentation November 2023 1 | © 2023 MicroVision, Inc. All rights reserved. Confidential and proprietary. Safe Harbor Statements This presentation of MicroVision, Inc. ("MicroVision," "the Company," "we," or "our"), and any accompanying oral presentation, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, among others: statements r ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to _________ Commission file number 001-34170 MicroVision, Inc. (Exact name of registrant as specified in its charter) Delaware 91-1600822 (Stat ...

MicroVision, Inc. (NASDAQ:MVIS) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Drew Markham - General Counsel Sumit Sharma - Chief Executive Officer Anubhav Verma - Chief Financial Officer Anand Balaji - Cantor Fitzgerald Operator Good afternoon, and welcome to the MicroVision Second Quarter 2023 Financial and Operating Results Conference call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn the ...

& MicroVision Investor Presentation August 2023 1 | © 2023 MicroVision, Inc. All rights reserved. Confidential and proprietary. Safe Harbor Statements This presentation of MicroVision, Inc. ("MicroVision," "the Company," "we," or "our"), and any accompanying oral presentation, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, among others: statements rel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34170 MicroVision, Inc. (Exact name of registrant as specified in its charter) Delaware 91-1600822 (State or Other Jurisd ...

Operator Please note that some of the information you will hear in today's discussion will include forward-looking statements, including, but not limited to, statements regarding our product development and performance, comparisons to our competitors, market opportunity, product sales and future demand, business and strategic opportunities, customer and partner engagement, projections of future operations and financial results, availability of funds, as well as statements containing words such as potential, ...

& MicroVision 1 | © 2023 MicroVision, Inc. All rights reserved. Confidential and proprietary. This presentation of MicroVision, Inc. ("MicroVision," "the Company," "we," or "our"), and any accompanying oral presentation, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, among others: statements relating to expectations regarding our future growth, profit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34170 MicroVision, Inc. (Exact name of registrant as specified in its charter) Delaware 91-1600822 (State or Other ...

I'm very pleased to continue demonstrating our financial rigor and discipline strategically deploying capital to execute this opportunistic transaction to acquire Ibeo for a purchase price of €15 million. This investment brought us and experienced and highly talented team of engineers, targeted customer relationships and a broad product portfolio. In fact, we're now benefiting from the past R&D investments done by Ibeo of over €200 million deployed over several years. This considerably reduces our go-to-mar ...

MicroVision, Inc. (NASDAQ:MVIS) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Drew Markham - Vice President, Secretary and General Counsel Sumit Sharma - Chief Executive Officer Anubhav Verma - Chief Financial Officer Conference Call Participants Andres Sheppard - Cantor Fitzgerald Operator Good day. And welcome to the MicroVision Third Quarter 2022 Financial and Operating Results Conference Call. At this time, all participants are in listen-only mode. [Operator Instructi ...